Organic Letters
Letter
(8) Brown, M. J.; Carter, P. S.; Fenwick, A. E.; Fosberry, A. P.;
Hamprecht, D. W.; Hibbs, M. J.; Jarvest, R. L.; Mensah, L.; Milner, P. H.;
O’Hanlon, P. J.; Pope, A. J.; Richardson, C. M.; West, A.; Witty, D. R.
Bioorg. Med. Chem. Lett. 2002, 12, 3171−3174.
Scheme 3. Synthesis of 16-π Electron Heteroaromatic
Isothiochromeno[1,8,7-bcd]indole (8)
(9) Van Vliet, L. A.; Rodenhuis, N.; Dijkstra, D.; Wikstrom, H.;
̈
Pugsley, T. A.; Serpa, K. A.; Meltzer, L. T.; Heffner, T. G.; Wise, L. D.;
Lajiness, M. E.; Huff, R. M.; Svensson, K.; Sundell, S.; Lundmark, M. J.
Med. Chem. 2000, 43, 2871−2882.
(10) Suarez, A.; Gohain, M.; Fernandez-Rodriguez, M.; Sanz, R. J. Org.
Chem. 2015, 80, 10421−10430.
(11) Benati, L.; Calestani, G.; Leardini, R.; Minozzi, M.; Nanni, D.;
Spagnolo, P.; Strazzari, S.; Zanardi, G. J. Org. Chem. 2003, 68, 3454−
3464.
dihydrothiopyran with an aptly substituted bromo group was
then shown to undergo Pd-catalyzed intramolecular Heck-type
cross-coupling to afford tetracyclic heteroaromatic isothio-
chromeno[1,8,7-bcd]indole. These newly synthesized hetero-
cyclic ring systems could be of high biological interest due to
their close resemblance with pharmaceutically active alkaloids.
(12) Wen, L.; Shen, Q.; Guo, W.; Li, M. Org. Chem. Front. 2016, 3,
870−874.
(13) Chen, X.; Qi, Z.; Zhang, S.; Kong, L.; Wang, Y.; Wang, X. Org.
Lett. 2015, 17, 42−45.
ASSOCIATED CONTENT
* Supporting Information
(14) Majumdar, K. C.; Ponra, S.; Ghosh, T. RSC Adv. 2012, 2, 1144−
1152.
■
S
(15) Moghaddam, F. M.; Khodabakhshi, M. R.; Kiamehr, M.;
Ghahremannejad, Z. Tetrahedron Lett. 2013, 54, 2685−2689.
(16) (a) Pedras, M. S. C.; Zaharia, I. L. Org. Lett. 2001, 3, 1213−1216.
(b) Pedras, M. S. C.; Jha, M. J. Org. Chem. 2005, 70, 1828−1834.
(17) Bourdais, J. Tetrahedron Lett. 1970, 11, 2895−2898.
(18) (a) Jha, M.; Blunt, B. Tetrahedron Lett. 2009, 50, 6044−6047.
(b) Jha, M.; Enaohwo, O.; Marcellus, A. Tetrahedron Lett. 2009, 50,
7184−7187. (c) Jha, M.; Chou, T. Y.; Blunt, B. Tetrahedron 2011, 67,
982−989. (d) Jha, M.; Enaohwo, O.; Guy, S. Tetrahedron Lett. 2011, 52,
684−687. (e) Jha, M.; Guy, S.; Chou, T. Tetrahedron Lett. 2011, 52,
4337−4341. (f) Jha, M.; Shelke, G. M.; Kumar, A. Eur. J. Org. Chem.
2014, 2014, 3334−3336. (g) Blanchard, D.; Cameron, T. S.; Jha, M. Mol.
Diversity 2013, 17, 827−834.
The Supporting Information is available free of charge on the
Experimental procedure, physical and spectral (1H NMR,
13C NMR, and HRMS) data and copy of 1H and 13C NMR
of the synthesized compounds 2a−f, 5a−t, 6a−l, 7a−i, 8,
9, and the X-ray crystallographic data and crystal structure
AUTHOR INFORMATION
■
Corresponding Author
ORCID
(19) Jha, M.; Edmunds, M.; Lund, K.; Ryan, A. Tetrahedron Lett. 2014,
55, 5691−5694.
(20) Jha, M.; Davis, C.; Fazzari, J.; Vitali, M. Tetrahedron Lett. 2014, 55,
7043−7046.
Notes
(21) Shelke, G. M.; Jha, M.; Kumar, A. Org. Biomol. Chem. 2016, 14,
3450−3458.
(22) Jha, M.; Shelke, G. M.; Cameron, T. S.; Kumar, A. J. Org. Chem.
2015, 80, 5272−5278.
The authors declare no competing financial interest.
(23) James, M. J.; Clubley, R. E.; Palate, K. Y.; Procter, T. J.; Wyton, A.
C.; O’Brien, P.; Taylor, R. J. K.; Unsworth, W. P. Org. Lett. 2015, 17,
4372−4375.
ACKNOWLEDGMENTS
■
The authors gratefully acknowledge the financial support
provided by the Natural Sciences and Engineering Research
Council of Canada (NSERC) and the Canada Foundation for
Innovation (CFI) to conduct this research.
(24) Smirnova, O. B.; Golovko, T. V.; Granik, V. G. Pharm. Chem. J.
2011, 44, 654−678.
(25) Cummings, M. M.; Clawson, R. W., Jr.; Sharma, S. B.; Byerly, R.
A.; Akhmedov, N. G.; Soederberg, B. C. G. Tetrahedron 2011, 67, 4753−
4757.
REFERENCES
■
(26) Varghese, V.; Hudlicky, T. Methods Princ. Med. Chem. 2014, 60,
(1) Gandeepan, P.; Cheng, C. Chem. - Asian J. 2015, 10, 824−838.
(2) For selected reviews, see: (a) Echavarren, A. M.; Hashmi, A. S.;
Toste, F. D. Adv. Synth. Catal. 2016, 358, 1347. (b) Kourra, C. M. B. K.;
Cramer, N. Nature 2015, 517, 440−441. (c) Wu, C.; Horibe, T.;
Jacobsen, C. B.; Toste, F. D. Nature 2015, 517, 449−454. (d) Wei, Y.;
Shi, M. ACS Catal. 2016, 6, 2515−2524.
225−250.
(27) (a) Shu, X.; Liu, X.; Xiao, H.; Ji, K.; Guo, L.; Qi, C.; Liang, Y. Adv.
Synth. Catal. 2007, 349, 2493−2498. (b) Gao, G.; Moore, D.; Xie, R.; Pu,
L. Org. Lett. 2002, 4, 4143−4146.
(28) Majumdar, K. C.; Debnath, P.; Alam, S.; Maji, P. K. Tetrahedron
Lett. 2007, 48, 7031−7033.
(3) (a) Sravanthi, T. V.; Manju, S. L. Eur. J. Pharm. Sci. 2016, 91, 1−10.
(b) Shiri, M. Chem. Rev. 2012, 112, 3508−3549. (c) Inman, M.; Moody,
C. J. Chem. Sci. 2013, 4, 29−41. (d) Sharma, V.; Kumar, P.; Pathak, D. J.
Heterocycl. Chem. 2010, 47, 491−502.
(4) (a) Takada, S.; Makisumi, Y. Chem. Pharm. Bull. 1984, 32, 872.
(b) Takada, S.; Ishizuka, N.; Sasatani, T.; Makisumi, Y.; Jyoyama, H.;
Hatakeyama, H.; Asanuma, F.; Hirose, K. Chem. Pharm. Bull. 1984, 32,
877.
(29) Single X-ray crystal structure of compound 6d. CCDC 1529611.
(30) Li, H. J.; Wang, L. Eur. J. Org. Chem. 2006, 5101−5102.
(31) Chandrasekhar, S.; Narsihmulu, C.; Sultana, S. S.; Reddy, N. R.
Org. Lett. 2002, 4, 4399−4401.
(5) (a) Berlin, K. D.; Benbrook, D. M.; Nelson, E. C. U.S. Patent
6586460, 2003. (b) Sugita, Y.; Hosoya, H.; Terasawa, K.; Yokoe, I.;
Fujisawa, S.; Sakagami, H. Anticancer Res. 2001, 21, 2629−2632.
(6) Quaglia, W.; Pigini, M.; Piergentili, A.; Giannella, M.; Gentili, F.;
Marucci, G.; Carrieri, A.; Carotti, A.; Poggesi, E.; Leonardi, A.;
Melchiorre, C. J. Med. Chem. 2002, 45, 1633−1643.
(7) Rogier, D. J., Jr.; Carter, J. S.; Talley, J. J. WO 2001049675, 2001.
D
Org. Lett. XXXX, XXX, XXX−XXX